IT1318960B1 - Metodo per la diagnosi della corea di huntington e sua modalita' ditrattamento basati sulla attivita' dell'adenilato ciclasi. - Google Patents
Metodo per la diagnosi della corea di huntington e sua modalita' ditrattamento basati sulla attivita' dell'adenilato ciclasi.Info
- Publication number
- IT1318960B1 IT1318960B1 IT2000MI002137A ITMI20002137A IT1318960B1 IT 1318960 B1 IT1318960 B1 IT 1318960B1 IT 2000MI002137 A IT2000MI002137 A IT 2000MI002137A IT MI20002137 A ITMI20002137 A IT MI20002137A IT 1318960 B1 IT1318960 B1 IT 1318960B1
- Authority
- IT
- Italy
- Prior art keywords
- disease
- activity
- huntington
- adenylate cyclase
- korea
- Prior art date
Links
- 102000030621 adenylate cyclase Human genes 0.000 title abstract 3
- 108060000200 adenylate cyclase Proteins 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 206010000117 Abnormal behaviour Diseases 0.000 abstract 2
- 208000023105 Huntington disease Diseases 0.000 abstract 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 102000007471 Adenosine A2A receptor Human genes 0.000 abstract 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 abstract 1
- 101150051188 Adora2a gene Proteins 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003040 circulating cell Anatomy 0.000 abstract 1
- 230000008878 coupling Effects 0.000 abstract 1
- 238000010168 coupling process Methods 0.000 abstract 1
- 238000005859 coupling reaction Methods 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Neurology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Physiology (AREA)
- Ecology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Pharmacology & Pharmacy (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI002137A IT1318960B1 (it) | 2000-10-03 | 2000-10-03 | Metodo per la diagnosi della corea di huntington e sua modalita' ditrattamento basati sulla attivita' dell'adenilato ciclasi. |
| AT01982391T ATE323287T1 (de) | 2000-10-03 | 2001-10-03 | Verfahren zur diagnose und behandlung von huntingtonserkrankung |
| EP01982391A EP1325335B1 (en) | 2000-10-03 | 2001-10-03 | Methods for diagnosing and treating huntington's disease |
| PCT/EP2001/011425 WO2002029408A2 (en) | 2000-10-03 | 2001-10-03 | Methods for diagnosing and treating huntington's disease |
| AU2002213990A AU2002213990A1 (en) | 2000-10-03 | 2001-10-03 | Methods for diagnosing and treating huntington's disease |
| US10/398,499 US20040023312A1 (en) | 2000-10-03 | 2001-10-03 | Method for diagnosing huntingtons disease and means of treating it |
| DE60118763T DE60118763D1 (de) | 2000-10-03 | 2001-10-03 | Verfahren zur diagnose und behandlung von huntingtonserkrankung |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000MI002137A IT1318960B1 (it) | 2000-10-03 | 2000-10-03 | Metodo per la diagnosi della corea di huntington e sua modalita' ditrattamento basati sulla attivita' dell'adenilato ciclasi. |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| ITMI20002137A0 ITMI20002137A0 (it) | 2000-10-03 |
| ITMI20002137A1 ITMI20002137A1 (it) | 2002-04-03 |
| IT1318960B1 true IT1318960B1 (it) | 2003-09-19 |
Family
ID=11445897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT2000MI002137A IT1318960B1 (it) | 2000-10-03 | 2000-10-03 | Metodo per la diagnosi della corea di huntington e sua modalita' ditrattamento basati sulla attivita' dell'adenilato ciclasi. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20040023312A1 (it) |
| EP (1) | EP1325335B1 (it) |
| AT (1) | ATE323287T1 (it) |
| AU (1) | AU2002213990A1 (it) |
| DE (1) | DE60118763D1 (it) |
| IT (1) | IT1318960B1 (it) |
| WO (1) | WO2002029408A2 (it) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7375194B2 (en) | 2002-01-28 | 2008-05-20 | California Institute Of Technology | Antibodies that bind to an epitope on the Huntington's disease protein |
| US20040049484A1 (en) * | 2002-09-11 | 2004-03-11 | Hamano Life Science Research Foundation | Method and apparatus for separating and extracting information on physiological functions |
| US8318446B2 (en) | 2008-12-05 | 2012-11-27 | California Institute Of Technology | DNA-damage-induced proteolysis |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9819382D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9819384D0 (en) * | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
-
2000
- 2000-10-03 IT IT2000MI002137A patent/IT1318960B1/it active
-
2001
- 2001-10-03 AU AU2002213990A patent/AU2002213990A1/en not_active Abandoned
- 2001-10-03 DE DE60118763T patent/DE60118763D1/de not_active Expired - Lifetime
- 2001-10-03 WO PCT/EP2001/011425 patent/WO2002029408A2/en active IP Right Grant
- 2001-10-03 US US10/398,499 patent/US20040023312A1/en not_active Abandoned
- 2001-10-03 AT AT01982391T patent/ATE323287T1/de not_active IP Right Cessation
- 2001-10-03 EP EP01982391A patent/EP1325335B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20040023312A1 (en) | 2004-02-05 |
| WO2002029408A2 (en) | 2002-04-11 |
| ITMI20002137A0 (it) | 2000-10-03 |
| WO2002029408A3 (en) | 2002-12-12 |
| ITMI20002137A1 (it) | 2002-04-03 |
| EP1325335A2 (en) | 2003-07-09 |
| DE60118763D1 (de) | 2006-05-24 |
| EP1325335B1 (en) | 2006-04-12 |
| ATE323287T1 (de) | 2006-04-15 |
| AU2002213990A1 (en) | 2002-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cole et al. | Psychological risk factors for HIV pathogenesis: mediation by the autonomic nervous system | |
| Gendron et al. | Temporal effects of left versus right middle cerebral artery occlusion on spleen lymphocyte subsets and mitogenic response in Wistar rats | |
| Garofalo et al. | Predicting chronicity in acute temporomandibular joint disorders using the research diagnostic criteria | |
| Giaroni et al. | P2 receptors in the murine gastrointestinal tract | |
| Gariballa | Malnutrition in hospitalized elderly patients: when does it matter? | |
| EP2264459A3 (en) | Method for the early detection of renal disease and injury | |
| AU2002327308A1 (en) | Methods for evaluating pathologic conditions using extracellular rna | |
| Muxfeldt et al. | Ambulatory arterial stiffness index or pulse pressure: which correlates better with arterial stiffness in resistant hypertension? | |
| WO2005098429A3 (en) | System and method for real-time diagnosis, treatment, and therapeutic drug monitoring | |
| Stone et al. | Retinal abnormalities in the Siamese cat | |
| Balla et al. | Phencyclidine-induced dysregulation of dopamine response to amphetamine in prefrontal cortex and striatum | |
| IT1318960B1 (it) | Metodo per la diagnosi della corea di huntington e sua modalita' ditrattamento basati sulla attivita' dell'adenilato ciclasi. | |
| Moore et al. | Prenatal ethanol exposure reduces parvalbumin-immunoreactive GABAergic neuronal number in the adult rat cingulate cortex | |
| Watkins et al. | Assessment of baroreflex control from beat‐to‐beat blood pressure and heart rate changes: a validation study | |
| WO2006070290A3 (en) | Agents and methods for early diagnosis and monitoring of alzheimer's disease and other neurological disorders | |
| Wallace et al. | Ambulatory blood pressure in 199 normal subjects, a collaborative study | |
| Calmels et al. | Relation between locomotion impairment, functional independence in retirement, and occupational strain resulting from work carried out during working life. Study of a sample population of 350 miners in the Loire valley in France. | |
| FR2828212B1 (fr) | Methodes de diagnostic et de pronostic de la maladie de parkinson | |
| Park et al. | An appraisal of the electrocardiographic criteria for diagnosis of left ventricular hypertrophy in Koreans: comparison to echocardiographic measurement of left ventricular mass | |
| Hossain et al. | Outcome of dapsone in the treatment of ashy dermatosis | |
| Koehler et al. | Effects of adult Ascaris suum and their antigens (total and trans-cuticular excretory–secretory antigen, cuticular somatic antigen) on intestinal nutrient transport in vivo | |
| Wu et al. | Changes in intramyocardial blood volume in response to non-flow-limiting stenosis can be quantified using mycardial contrast echocardiography | |
| Karppi et al. | Outcome of aged patients in Finnish supervised home care | |
| Maynard et al. | The acoustic startle reflex in Sprague-Dawley rats is altered by permanent middle cerebral artery occlusion | |
| Cainelli et al. | Spontaneous monitoring of adverse reactions to drugs by Italian dermatologists: a pilot study |